Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants

Zarychta, Elżbieta; Rhone, Piotr; Bielawski, Kornel; Michalska, Marta; Rość, Danuta; Ruszkowska-Ciastek, Barbara

doi:10.1016/j.advms.2019.02.001

Cited by 3 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cut-off value of circulating EPCs count was established at 10.57 cells/μL, due to our previous findings, where we noted that the median value of circulating EPCs was 10.57 cells/μL in breast cancer patients as compared to healthy postmenopausal women as well as according to ROC analysis made in the current study, where the cut-off value was set at 10.55 cells/μL, which discriminates between the relapse disease group and the non-relapse disease patients [9]. This observation is compatible with our former investigations, since we observed that a lower number of circulating EPCs has been associated with higher tumour grading according to Elston–Ellis as well as with higher Ki67 expression [9,11]. We proposed in our previous paper that circulating endothelial progenitors are crucial agents at the early stage of tumour growth [9].…”

Section: Discussionsupporting

confidence: 88%

“…FISH was performed using a dual HER2/Cep17 probe. Detailed methodology has been published in our previous work [9,11].…”

Section: Methodsmentioning

confidence: 99%

“…However, the pathophysiological role of circulating EPCs in many cancers is of interest to many research groups. In our previous study, we reported that circulating EPCs were significantly higher in breast cancer patients and the level was inversely associated with the expression of the proliferation marker (Ki67) and the histological grading of the breast cancer [9,11]. It has been established that circulating EPCs counts might either elevate or even drop after surgery [12,13].…”

Section: Introductionmentioning

confidence: 99%

“…The aim of this study was to document the different effects of adjuvant therapy on circulating EPCs, which are considered important biomarkers indicative of neovascularisation. According to our previous studies, we suggest that alterations in the number of circulating EPCs in patients with invasive breast cancers can indicate the advancement of the malignancy [9,11] but in the current study, we aimed to explore whether the fluctuation in the circulating EPCs count can predict treatment response and disease recurrence.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence

Rhone¹,

Bielawski

Ziółkowska

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

Neoangiogenesis is mediated by circulating bone marrow-derived endothelial progenitors (circulating EPCs). The aim of the study was the quantification of circulating EPCs from the peripheral blood mononuclear cells of invasive breast cancer (IBrC) patients by flow cytometry, before and after cancer adjuvant treatment. A total of 88 stage IA-IIB primary IBrC patients were enrolled prospectively. Circulating EPCs with the immune-phenotype CD45−CD34+CD133+CD31+ were assessed. Treatment significantly reduced the number of EPCs/µL in the general IBrC cohort. However, there was a relevant elevation in the number of circulating EPCs after nine months of adjuvant treatment in the group of patients aged ≥ 55 years, of T2 clinical type, with nodal involvement (N1) and Ki67 expression > 15%. Follow-up revealed a significantly higher incidence of disease relapse in breast cancer patients with low pre-treatment circulating EPCs levels compared with those with a high baseline circulating EPCs count. The receiver-operating characteristic curve identified a tumour diameter of 2.1 cm as the best cut-off value to discriminate between disease-relapse subjects and non-relapse disease cases. Our study strongly indicates that, next to tumour diameter and Ki67 expression, circulating bone marrow-derived EPCs may serve as useful markers for predicting therapeutic outcomes as well as a future prognosis.

show abstract

Section: Discussionsupporting

confidence: 88%

“…FISH was performed using a dual HER2/Cep17 probe. Detailed methodology has been published in our previous work [9,11].…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence

Rhone¹,

Bielawski

Ziółkowska

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Elevated levels of VEGF-A in BC are linked to aggressive tumor behavior and poor prognosis [ 26 , 37 ]. Tumors overexpressing HER2 also over-release VEGF-A.…”

Section: Angiogenesismentioning

confidence: 99%

Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View

Zarychta

Ruszkowska-Ciastek

2022

Biomedicines

Self Cite

View full text Add to dashboard Cite

With almost 2.3 million new cases and 685 thousand fatal events in 2020 alone, breast cancer remains one of the main causes of morbidity and mortality in women worldwide. Despite the increasing prevalence of the disease in recent years, the number of deaths has dropped—this is mostly the result of better diagnostic and therapeutic opportunities, allowing to recognize and treat breast cancer earlier and more efficiently. However, metastatic disease still remains a therapeutic challenge. As mechanisms of tumor spread are being explored, new drugs can be implemented in clinical practice, improving the outcomes in patients with advanced disease. Formation of metastases is a complex process, which involves activation of angiogenesis, vasculogenesis, chemotaxis, and coagulation. The actions, which occur during metastatic spread are interrelated and complementary. This review summarizes their importance and mutual connections in formation of secondary tumors in breast cancer.

show abstract

Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer

Grochoła-Małecka

Czajka-Francuz

Owczarek

et al. 2022

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

WstępAngiogeneza nowotworowa jest procesem regulowanym przez wiele cytokin i czynników wzrostu, spośród których znaczącą rolę odgrywają czynnik wzrostu śródbłonka naczyń (vascular endothelial growth factor – VEGF), drugi rozpuszczalny receptor dla śródbłonkowego czynnika wzrostu (soluble vascular endothelial growth factor receptor 2 – sVEGFR-2) i galektyna-3. Dane literaturowe dotyczące oceny zmian stężenia VEGF, sVEGFR-2 oraz galektyny-3 w trakcie chemioterapii (chemotherapy – CTH) raka piersi (breast cancer – BC) są niejednoznaczne. Celem niniejszej pracy była analiza stężenia VEGF-A, sVEGFR-2 oraz galektyny-3 w surowicy pacjentek z rakiem piersi, rozpoczynających adjuwantową i neoadjuwantową chemioterapię oraz ocena zmian stężenia tych cytokin w trakcie leczenia.Materiał i metodyJednoośrodkowe badanie objęło 98 pacjentek z miejscowo zaawansowanym rakiem piersi, w tym 56 poddanych adjuwantowej i 42 neoadjuwantowej terapii. Stężenie VEGF-A, sVEGFR-2 i galektyny-3 w surowicy krwi oceniono na początku leczenia oraz po 2 miesiącach terapii.WynikiNie stwierdzono istotnych różnic pomiędzy stężeniami VEGF-A, sVEGFR-2 oraz galektyny-3 w surowicy pacjentek poddanych adjuwantowej i neoadjuwantowej chemioterapii. Nie wykazano również zależności między stężeniem tych cytokin w surowicy a stopniem zaawansowania klinicznego raka piersi. W trakcie przedoperacyjnej chemioterapii odnotowano znaczące zwiększenie stężenia VEGF-A, sVEGFR-2 i galektyny-3, jednakże zarówno wyjściowe stężenia cytokin, jak i zmiany w czasie nie miały znaczenia predykcyjnego dla uzyskania całkowitej odpowiedzi patologicznej.WnioskiStężenia VEGF-A, sVEGFR-2 oraz galektyny-3 w surowicy nie korelują ze stopniem zaawansowania klinicznego ani masą nowotworu u pacjentek z miejscowo zaawansowanym rakiem piersi. Wyjściowe stężenia VEGF-A, sVEGFR-2 i galektyny-3 oraz zaobserwowany wzrost stężeń tych cytokin w surowicy w trakcie chemioterapii nie mają wartości predykcyjnej dla jej skuteczności.

show abstract

Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants

Cited by 3 publications

References 22 publications

Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence

Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence

Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View

Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer

Contact Info

Product

Resources

About